A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents Investing in our common stock involves significant risks, some of which are described below. In evaluating our business, investors should carefully consider the following risk factors. These risks and uncertainties summarized above and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem immaterial may also impair our business operations. Please see page 2 of this Annual Report for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. Risk Factors Summary Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business, including those described in Part I, Item 1A.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | 15M |
| Net Income | -16M | -64M | -66M | -61M | -111M | -3.5M |
| EPS | $-0.64 | $-2.36 | $-2.44 | $-2.69 | $-12.41 | $-1.76 |
| Free Cash Flow | -96M | -61M | -64M | -50M | -22M | -13M |
| ROIC | -51.3% | -101.6% | -62.5% | -38.2% | -81.2% | -10.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.34 | 0.26 | 0.16 | 0.16 | -0.09 |
| Dividends/Share | $0.00 | - | - | - | $0.49 | - |
| Operating Income | -108M | -67M | -72M | -63M | -111M | -2.5M |
| Operating Margin | 0.0% | - | - | - | - | -17.5% |
| ROE | -9.9% | -80.8% | -62.5% | -38.2% | -81.2% | - |
| Shares Outstanding | 47M | 27M | 27M | 22M | 9M | 21M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 20M | 0 | 15M | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -11M | -24M | -2.5M | -111M | -63M | -72M | -67M | -108M |
| Op. Margin | -55.5% | N/A | -17.5% | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -10M | -23M | -3.5M | -111M | -61M | -66M | -64M | -16M |
| Net Margin | -51.6% | N/A | -23.9% | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 1.9M | 0 | 74M | 0 | 0 | 2.6M | 2.6M |
| Returns on Capital | ||||||||
| ROIC | -17.7% | -63.7% | -10.7% | -81.2% | -38.2% | -62.5% | -101.6% | -51.3% |
| ROE | -17.7% | -63.7% | N/A | -81.2% | -38.2% | -62.5% | -80.8% | -9.9% |
| ROA | -16.2% | -58.3% | -18.5% | -70.1% | -32.8% | -49.7% | -62.8% | -9.4% |
| Cash Flow | ||||||||
| Op. Cash Flow | -5.8M | -24M | -13M | -22M | -50M | -60M | -60M | -95M |
| Free Cash Flow | -5.8M | -24M | -13M | -22M | -50M | -64M | -61M | -96M |
| Owner Earnings | -9.3M | -25M | -13M | -25M | -59M | -72M | -71M | -106M |
| CapEx | 38K | 237K | 0 | 46K | 444K | 4.0M | 1.7M | 0 |
| Maint. CapEx | 47K | 77K | 9K | 105K | 159K | 169K | 193K | 193K |
| Growth CapEx | 0 | 160K | N/A | 0 | 285K | 3.8M | 1.5M | 0 |
| D&A | 47K | 77K | 9K | 105K | 159K | 169K | 193K | 193K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 4.4M | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | 2.0% | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.4M | 1.1M | 139K | 2.1M | 9.6M | 12M | 11M | 11M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | -3.4M | N/A | N/A | N/A | N/A | -163M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 163M |
| Long-Term Debt | N/A | N/A | 1.1M | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.09 | 0.09 | -0.09 | 0.16 | 0.16 | 0.26 | 0.34 | 0.00 |
| Interest Coverage | -14.4 | -23.7 | -3.1 | -167.2 | -272.5 | -311.4 | -438.0 | -438.0 |
| Equity | 59M | 37M | -12M | 136M | 158M | 105M | 52M | 157M |
| Total Assets | 64M | 40M | 19M | 158M | 184M | 132M | 70M | 167M |
| Total Liabilities | 5.5M | 3.4M | 31M | 22M | 26M | 27M | 18M | 9.8M |
| Intangibles | N/A | N/A | N/A | 7.6M | N/A | N/A | N/A | N/A |
| Retained Earnings | -119M | -142M | -33M | -143M | -203M | -269M | -333M | -333M |
| Working Capital | 59M | 36M | -11M | 136M | 161M | 98M | 44M | 44M |
| Current Assets | 64M | 40M | 19M | 151M | 180M | 125M | 61M | 61M |
| Current Liabilities | 5.5M | 3.3M | 30M | 15M | 19M | 26M | 17M | 17M |
| Per Share Data | ||||||||
| EPS | -4.65 | -8.55 | -1.76 | -12.41 | -2.69 | -2.44 | -2.36 | -0.64 |
| Owner EPS | -4.15 | -9.19 | -0.61 | -2.76 | -2.64 | -2.66 | -2.62 | -2.26 |
| Book Value | 26.24 | 13.42 | -0.59 | 15.29 | 7.04 | 3.90 | 1.94 | 3.33 |
| Cash Flow/Share | -2.60 | -8.76 | -0.61 | -2.51 | -2.21 | -2.21 | -2.21 | -0.33 |
| Dividends/Share | N/A | N/A | N/A | 0.49 | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.2M | 2.7M | 20.9M | 8.9M | 22.5M | 27.0M | 27.0M | 47.1M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -5.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 1.0 | 0.6 | N/A | 1.6 | 1.7 | 0.5 | 1.7 | 1.0 |
| Price/Sales | 5.8 | N/A | 23.3 | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -10.2% | -101.7% | -4.0% | -10.5% | -18.5% | -112.4% | -70.6% | -58.7% |
| Market Cap | 57M | 24M | 320M | 215M | 271M | 57M | 87M | 164M |
| Avg. Price | 52.07 | 19.26 | 16.21 | 25.25 | 15.19 | 7.18 | 1.91 | 3.47 |
| Year-End Price | 25.65 | 8.70 | 15.30 | 24.09 | 12.03 | 2.10 | 3.21 | 3.47 |
Whitehawk Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Whitehawk Therapeutics, Inc. (WHWK) has a 5-year average return on invested capital (ROIC) of -58.8%. This is below average and may indicate limited pricing power.
Whitehawk Therapeutics, Inc. (WHWK) has a market capitalization of $164M. It is classified as a small-cap stock.
Whitehawk Therapeutics, Inc. (WHWK) does not currently pay a regular dividend.
Whitehawk Therapeutics, Inc. (WHWK) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Whitehawk Therapeutics, Inc. (WHWK) generated $-61 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Whitehawk Therapeutics, Inc. (WHWK) has a debt-to-equity ratio of 0.34. This indicates a conservatively financed balance sheet.
Whitehawk Therapeutics, Inc. (WHWK) reported earnings per share (EPS) of $-2.36 in its most recent fiscal year.
Whitehawk Therapeutics, Inc. (WHWK) has a return on equity (ROE) of -80.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Whitehawk Therapeutics, Inc. (WHWK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Whitehawk Therapeutics, Inc. (WHWK) has a book value per share of $1.94, based on its most recent annual SEC filing.